二肽基肽酶-4抑制剂的临床疗效和安全性评价

Efficacy and Safety Evaluation on Dipeptidyl Peptidase-Ⅳ Inhibitor

目的:二肽基肽酶-4(DPP-4)抑制剂的问世是21世纪药学研究的丰硕成果,其作用途径独特,迂回在胰岛β细胞和胰岛素之外,通过抑制DPP-4活性延长胰高血糖素样肽-1(GLP-1)的作用时间和促进胰岛素分泌,从而降低血糖水平,本文对其作用特点和临床应用进行评价。方法:通过对国内外近期文献进行分析。结果与结论:DPP-4抑制剂通过抑制内源性的GLP-1的降解,提高GLP-1的水平,进而促进葡萄糖依赖的胰岛素分泌和抑制胰高血糖素产生,从而控制血糖的稳定。DPP-IV抑制剂具有不影响体质量和不增加低血糖风险的优势,在2型糖尿病的治疗中发挥着越来越重要的作用。

Dipeptidyl peptidase-4 （DPP-4） Inhibitor has pharmaceutical research fruitful results of twenty-first century, it has unique effect channel, except circuitous pancreatic islet-beta cells and insulin, the inhibition of DPP-4 can prolong the action of glucagon-like peptide-land improve insulin secretion, so as to lower the glucose level, to summarize the aspect of clinical application and evaluation. METHODS：To collecte medical literatures in recent years at home and abroad. RESULTS ＆ CONCLUSION：the dipeptidyl pepdase-4inhibitor is a validated target for the treatment of type 2 diabetes. DPP-4 inhibitor significantly lower bloodglueose levels in patients with type 2 diabetes without common side effects of body weight gain, hypoglycemia and gastrointestinal disturbances, therfore, DPP-4 inhibitor play an increasingly important role in the treatment of type 2 diabetes.